Identification and Characterization of a Selective Peroxisome Proliferator-Activated Receptor (cid:1) / (cid:2) (NR1C2) Antagonist

The identification of small molecule ligands for the peroxisome proliferator-activated receptors (PPARs) has been instrumental in elucidating their biological roles. In particular, agonists have been the focus of much of the research in the field with relatively few antagonists being described and all of those being selective for PPAR (cid:3) or PPAR (cid:4) . The comparison of these agonist and antagonist ligands in cellular and animal systems has often led to surprising results and new insights into the bi-ology of the PPARs. The PPAR (cid:1) / (cid:2) receptor is emerging as an important regulator of energy metabolism, inflammation, and cell growth and differ-entiation; however, only agonist ligands have been described for this receptor thus far. Here we de-scribe the first report of a PPAR (cid:1) / (cid:2) small molecule antagonist ligand. This antagonist ligand will be a useful tool for elucidating the biological roles of PPAR (cid:1) / (cid:2)

[1]  D. McDonnell,et al.  The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. , 2007, Molecular endocrinology.

[2]  T. Willson,et al.  Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor &dgr; Agonist , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Lazar,et al.  The N‐CoR complex enables chromatin remodeler SNF2H to enhance repression by thyroid hormone receptor , 2006, The EMBO journal.

[4]  S. Yoshida,et al.  Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. , 2006, Biochemical pharmacology.

[5]  T. Kodama,et al.  Peroxisome proliferator-activated receptor δ (PPARδ), a novel target site for drug discovery in metabolic syndrome , 2006 .

[6]  M. Maffei,et al.  Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. , 2006, Endocrine reviews.

[7]  Jerrold M. Olefsky,et al.  PPARδ regulates glucose metabolism and insulin sensitivity , 2006 .

[8]  Arnaud Pillon,et al.  Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands , 2005 .

[9]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[10]  R. DuBois,et al.  Wnt and Cyclooxygenase-2 Cross-talk Accelerates Adenoma Growth , 2004, Cell cycle.

[11]  R. Evans,et al.  Regulation of Muscle Fiber Type and Running Endurance by PPARδ , 2004, PLoS biology.

[12]  D. Vanderwall,et al.  Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. , 2004, Molecular endocrinology.

[13]  Johan Auwerx,et al.  Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Katzenellenbogen,et al.  Molecular sensors of estrogen receptor conformations and dynamics. , 2003, Molecular endocrinology.

[15]  T. Willson,et al.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity , 2003 .

[16]  J. Schwabe,et al.  A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease , 2003, Nature Structural Biology.

[17]  W. Wahli,et al.  A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. , 2002, Molecular endocrinology.

[18]  T. Willson,et al.  Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. , 2002, Biochemistry.

[19]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[20]  Yanhong Shi,et al.  The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[22]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[24]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[25]  A. Burdick,et al.  The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. , 2006, Cellular signalling.

[26]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[27]  C. Glass,et al.  Nuclear receptor coactivators. , 2000, Advances in pharmacology.